Prevalence, clinical characteristics and outcomes of hypoxic hepatitis in critically ill patients

2021 ◽  
pp. 1-8
Author(s):  
Sigrún Jonsdottir ◽  
Margrét B. Arnardottir ◽  
Jóhannes A. Andresson ◽  
Helgi K. Bjornsson ◽  
Sigrun H. Lund ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Clinical Characteristics ◽  
Hypoxic Hepatitis

Clinical characteristics of critically ill patients with suspected influenza during the 2009-10 and 2013-14 outbreaks

2017 ◽  
Vol 38 ◽  
pp. 73-77
Author(s):  
Miguel J. Franquiz ◽  
Paul G. Saleeb ◽  
Carl B. Shanholtz ◽  
Jeffrey P. Gonzales
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Clinical Characteristics

462 HYPOXIC HEPATITIS – UNDERLYING CONDITIONS AND RISK FACTORS FOR MORTALITY IN CRITICALLY ILL PATIENTS

2009 ◽  
Vol 50 ◽  
pp. S174
Author(s):  
V. Fuhrmann ◽  
N. Kneidinger ◽  
H. Herkner ◽  
G. Heinz ◽  
M. Nikfardjam ◽  
...  
Keyword(s):  
Risk Factors ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Hypoxic Hepatitis

scholarly journals Clinical characteristics and outcomes of patients with heart failure admitted to the intensive care unit with coronavirus disease 2019 (COVID19): a multicenter cohort study

2021 ◽  
Vol 20 (Supplement_1) ◽  
Author(s):  
H Badreldin ◽  
DR Hafidh ◽  
DR Bin Saleh ◽  
DR Al Sulaiman ◽  
DR Al Juhani ◽  
...  
Keyword(s):  
Heart Failure ◽  
Intensive Care Unit ◽  
Intensive Care ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Clinical Characteristics ◽  
P Value ◽  
Heart Failure Patients ◽  
Icu Admission ◽  
Patients With Heart Failure

Abstract Funding Acknowledgements Type of funding sources: None. Background Patients with heart failure in the setting of COVID-19 requiring admission to the intensive care unit may present a set of unique challenges. There is limited data to describe the clinical characteristics and outcomes in this subset of the patient population. Purpose The study"s purpose was to extensively describe the characteristics and outcomes of heart failure patients admitted to the intensive care unit with COVID-19 compared to non-heart failure patients . Methods We conducted a multicenter, prospective analysis for all adult critically ill patients with heart failure admitted to intensive care units (ICUs) between March 1 to August 31, 2020, with an objectively confirmed diagnosis of COVID-19. Results A total of 723 critically ill patients with COVID-19 had been admitted in ICUs, 59 patients with heart failure, and 664 patients with no heart failure before ICU admission. Heart failure patients had significantly more comorbid conditions such as diabetes mellitus, hypertension, dyslipidemia, atrial fibrillation, and acute coronary syndrome. Higher baseline severity scores (APACHE II & SOFA score) and nutritional risk (NUTRIC Score) were observed in heart failure patients. Also, heart failure patients had more acute kidney injury during ICU admission and required more mechanical ventilation within 24 hours of ICU admission. Patients with heart failure had a similar incidence of thrombosis compared to patients with no heart failure. Critically ill patients with COVID-19 and heart failure had similar ICU length of stay (LOS), mechanical ventilation duration, and hospital LOS compared to patients with no heart failure. During ICU stay, patients with heart failure had more in-hospital and ICU deaths in comparison to the non-heart failure group (64.3% vs. 44.6%, P-value <0.01) and (54.5% vs. 39%, P-value = 0.02) respectively. Conclusion In this observational study evaluating the clinical characteristics and outcomes of critically ill COVID-19 patients with heart failure, patients with COVID-19 and heart failure had similar ICU LOS, duration of MV and hospital LOS, thrombosis rate compared to patients with no heart failure. However, during ICU stay, patients with heart failure had more in-hospital and ICU deaths than the non-heart failure group.

scholarly journals Clinical characteristics and outcomes of critically Ill patients with COVID-19 in Northeast Ohio: low mortality and length of stay

2020 ◽  
Vol 35 (4) ◽  
pp. 242-248
Author(s):  
Francois Abi Fadel ◽  
Mohammed Al-Jaghbeer ◽  
Sany Kumar ◽  
Lori Griffiths ◽  
Xiaofeng Wang ◽  
...  
Keyword(s):  
Length Of Stay ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Clinical Characteristics

scholarly journals Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19

2021 ◽  
Vol 8 ◽  
Author(s):  
Shoji Hashimoto ◽  
Kazuyuki Yoshizaki ◽  
Kazuko Uno ◽  
Heita Kitajima ◽  
Tsuyoshi Arai ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Clinical Characteristics ◽  
Meta Analysis ◽  
High Ratio ◽  
Igg Antibody ◽  
Rapid Improvement ◽  
Cytokines And Chemokines ◽  
Ifn Γ ◽  
Tocilizumab Monotherapy

Background and Aim: Tocilizumab, a humanized anti-IL-6 receptor antibody, has been used to treat severely to critically ill patients with COVID-19. A living systematic review with meta-analysis of recent RCTs indicates that the combination therapy of corticosteroids and tocilizumab produce better outcomes, while previous observational studies suggest that tocilizumab monotherapy is beneficial for substantial numbers of patients. However, what patients could respond to tocilizumab monotherapy remained unknown.Methods: In this retrospective study we evaluated the effects of tocilizumab monotherapy on the clinical characteristics, serum biomediator levels, viral elimination, and specific IgG antibody induction in 13 severely to critically ill patients and compared with those of dexamethasone monotherapy and dexamethasone plus tocilizumab.Results: A single tocilizumab administration led to a rapid improvement in clinical characteristics, inflammatory findings, and oxygen supply in 7 of 11 patients with severe COVID-19, and could recover from mechanical ventilation management (MVM) in 2 patients with critically ill COVID-19. Four patients exhibited rapidly worsening even after tocilizumab administration and required MVM and additional methylprednisolone treatment. Tocilizumab did not delay viral elimination or inhibit IgG production specific for the virus, whereas dexamethasone inhibited IgG induction. A multiplex cytokine array system revealed a significant increase in the serum expression of 54 out of 80 biomediators in patients with COVID-19 compared with that in healthy controls. Compared with those who promptly recovered in response to tocilizumab, patients requiring MVM showed a significantly higher ratio of basal level of ferritin/CRP and a persistent increase in the levels of CRP and specific cytokines and chemokines including IL-6, IFN-γ, IP-10, and MCP-1. The basal high ratio of ferritin/CRP was also associated with clinical deterioration even in patients treated with dexamethasone and tocilizumab.Conclusion: Tocilizumab as monotherapy has substantial beneficial effects in some patients with severe COVID-19, who showed a relatively low level of the ratio of ferritin/CRP and prompt reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1. The high ratio of ferritin/CRP is associated with rapid worsening of pneumonia. Further evaluation is warranted to clarify whether tocilizumab monotherapy or its combination with corticosteroid is preferred for severely to critically ill patients with COVID-19.

Sign in / Sign up

Export Citation Format

Share Document